PEDIG | ATS18 – Pediatric Amblyopia Study
Why we are doing this study:
This is a study for children age 5 year to less than 17 years old who have AMBLYOPIA, sometimes referred to as lazy eye, a condition where one of the eyes does not work as well as the other. This study will look at using a game played on an iPad® or putting a patch over the good eye to treat amblyopia. We are trying to find out if playing this game works compared to patching.
Who can be in the study:
Children age 5 years to less than 17 years with amblyopia . No amblyopia treatment (atropine, patching, Bangerter, vision therapy) in the past 2 weeks
Specific screening questions will be asked before scheduling a study appointment.
What the study involves:
The length of the study is 16 weeks with check-ups at 4, 8, 12, and 16 weeks. The length of the visits will depend on how old your child is. Visits can range from 1 ½ hours to 3 hours. At the end of your first study visit, your child will be randomized (like the toss of a coin) to either computer game or patching. Your child will be asked to play a computer game on an iPad for 1 hour a day, 7 days a week for 16 weeks OR your child will be asked to wear a patch 2 hours per day, 7 days per week for 16 weeks. At each visit, your child will:
- Have his/her vision checked.
- Have stereoacuity (depth perception) checked.
- Have his/her eye alignment checked.
- Complete other procedures designed to see if your child’s qualifies for the study.
- Parents will complete a questionnaire at each visit.
Will you directly benefit from the study?
There may or may not be a benefit to your child by being in the study, but there is no guarantee.
Other things you should know about the study:
- Parental permission is required for minors (under age 18) to participate in this study, so a parent will need to be present during the enrollment visit.
- The study will loan an ipad to your child.
- You will receive $50 for each completed visit for your time for the study.
Principle Investigator: Marilyn Vricella
For more information, contact the Clinical Vision Research Center.